AGL3 Antibody

Anti-ANGPTL3 Antibodies

ANGPTL3 (angiopoietin-like protein 3) is a liver-derived protein that inhibits lipoprotein lipase (LPL) and endothelial lipase (EL), influencing lipid metabolism. Anti-ANGPTL3 antibodies have emerged as therapeutic candidates for hyperlipidemia and kidney diseases.

Key Findings:

• REGN1500: A fully human monoclonal antibody targeting ANGPTL3 demonstrated:

  • ≥50% reduction in plasma triglycerides (TGs) in normolipidemic mice .

  • Decreased LDL-C and HDL-C in dyslipidemic mice and cynomolgus monkeys, even in severe hypertriglyceridemia (TG >400 mg/dl) .

  • Mechanism: Reverses ANGPTL3-induced LPL inhibition, enhancing lipid clearance .

• 5E5F6 mAb: An agonistic anti-ANGPTL3 monoclonal antibody targeting the fibronectin-like domain (FLD):

  • Attenuated podocyte injury in adriamycin-induced nephropathy by reducing mitochondrial dysfunction .

  • Inhibits ANGPTL3-FLD binding to integrin β3, a pathway implicated in proteinuria .

Experimental Data:

Anti-GLI-3 Antibodies

GLI-3 is a transcription factor in the Hedgehog signaling pathway. Anti-GLI-3 antibodies (e.g., AF3690) are tools for detecting GLI-3 in research.

Key Applications:

• AF3690 (Goat Anti-Human/Mouse GLI-3):

  • Detects GLI-3 at ~85 kDa in Western blots (mouse embryo lysates) .

  • Used in chromatin immunoprecipitation (ChIP) to study GLI-3-regulated genes (e.g., gli-1 promoter in Jurkat cells) .

  • Localizes GLI-3 in HeLa cells via fluorescent immunocytochemistry .

Experimental Workflow (Western Blot):

1. Sample: Mouse embryo tissue lysates.

2. Primary Antibody: AF3690 (1 µg/mL).

3. Secondary Antibody: HRP-conjugated anti-goat IgG.

4. Result: Specific band at 85 kDa under reducing conditions .

Ambiguity and Contextual Notes

• The term "AGL3" appears in one study as a reference serum (AGL3) for calibrating anti-PLIN1 autoantibody assays , unrelated to a distinct antibody compound.

• No sources explicitly describe an antibody named "AGL3." The closest matches are anti-ANGPTL3 or anti-GLI-3 antibodies, suggesting potential nomenclature errors in the query.

Therapeutic and Research Implications